Observational studyBMJ open gastroenterology2026
Baseline characteristics of participants recruited into the COLO-COHORT study: a UK-wide resource for colorectal cancer prevention.
Observational study in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveTo describe the design, recruitment, and baseline characteristics of the first phase of COLO-COHORT and to establish this population as a resource for colorectal cancer (CRC) prevention research.
methodsCOLO-COHORT is a prospective, multicentre observational study recruiting adults undergoing colonoscopy through screening and routine National Health Service referral pathways within a 32-site UK network. We present descriptive data from the first 4754 participants, recruited through 27 Phase 1 sites, including demographics, lifestyle factors, clinical characteristics, biospecimen availability and colonoscopy outcomes.
resultsParticipants had a median age of 64 years (IQR 57-70), and 54.3% were male. Overweight (38.0%) and obesity (30.5%) were common, and cardiometabolic comorbidities were prevalent (11.8% with type II diabetes; 39.4% with hypertension). Colorectal neoplasia was identified at colonoscopy in over half of participants (56.1%), with histologically characterised data available on polyp type, size, morphology and anatomical location. Core demographic and clinical variables were available for >95% of participants, with colonoscopy findings recorded for all. Linked blood and stool microbiome biospecimens were available for approximately 80% and 40% of participants, respectively.
conclusionThis paper establishes and characterises COLO-COHORT's Phase 1 study cohort as a well-phenotyped resource, representing a population of individuals undergoing colonoscopy via UK screening and routine clinical pathways. This cohort will support and underpin future collaborative clinical, epidemiological and translational research in CRC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.